Mitsui Chemicals: F3/27 1Q Results 1st Impression: Upbeat as Three Growth Domains All Top Expectations

Research evidence excerpt

M

Update

August 5, 2026 04:55 AM GMT

Mitsui Chemicals (4183) | Japan

Morgan Stanley MUFG Securities Co., Ltd.+

Takato Watabe

Equity Analyst

F3/27 1Q Results 1st Impression:

Upbeat as Three Growth

Domains All Top Expectations

Ryoichi Watanabe

Equity Analyst

Kayoko Shoji

Research Associate

Kano Fujita

Research Associate

1Q earnings top our estimates, consensus: Mitsui Chemicals announced results at

13:00 JST. F3/27 1Q core OP was +88% YoY at ¥50.1bn, somewhat above our

¥42.0bn estimate (FactSet consensus: ¥36.2bn). Earnings topped our estimates

across the board, with Mobility the largest overshoot. The firm disclosed F3/27 1H

OP guidance, calling for core OP +71% YoY at ¥76.0bn (our estimate: ¥55.0bn;

FactSet consensus: ¥54.0bn). Full-F3/27 guidance was left unchanged. We will

Mitsui Chemicals (4183.T, 4183 JT)

report further details following the online results briefing at 16:00 JST today. We

Petrochemical Majors | Japan

see positive implications for the share price.

Stock Rating

Industry View

Price target

Shr price, close (Aug 4, 2026)

Mkt cap, curr, basic (bn)

Avg daily trading value (bn)

Related reports:

Overweight

Attractive

¥2,900

¥2,098

¥789.8

¥5.5

Petrochemical Majors: FY26 Apr–Jun Results Preview: Expect Consensus Overshoot

(Jul 23, 2026)

Mitsui Chemicals: Visit to Korean MDI JV: Confirming Drivers of Competitiveness and

High Profitability (Jul 6, 2026)

Mitsui Chemicals: F3/29 Core OP to Approach Record High (Jul 2, 2026)

Morgan Stanley does and seeks to do business with

companies covered in Morgan Stanley Research. As a result,

investors should be aware that the firm may have a conflict of

interest that could affect the objectivity of Morgan Stanley

Research. Investors should consider Morgan Stanley

Research as only a single factor in making their investment

decision.